Growing Medical Acceptance of Psychedelics – The Daily Dive feat Derek Welsh of Revive Therapeutics

For our final episode of The Daily Dive this week, host Cassandra Leah is joined by that of Derek Welsh of Revive Therapeutics (CSE: RVV), and founder of Psilocin Pharma Corp, a subsidiary of the company. Derek joins us to discuss his outlook on that of the psychedelics market as a whole, and discuss what Revive is working on from a psychedelics standpoint.

Psilocin Pharma, which was acquired by Revive Therapeutics earlier this year, is the psychedelic-focused arm of the company. The company has developed production solutions for the active compound psilocybin. The firm has developed six formulations to date, while owning a robust pipeline of ongoing research and development work within the psychedelics space.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

Revive Therapeutics Granted FDA Approval For Phase 3 Clinical Trial For Bucillamine In COVID-19 Treatment

It’s a big day for Revive Therapeutics (CSE: RVV) (OTC: RVVTF). The company announced this...

Friday, July 31, 2020, 09:16:29 AM

Roadman Investments To Establish Psychedelic Conference for Investors

Roadman Investments (TSXV: LITT), a firm focused on the production of mushrooms, announced this morning...

Thursday, September 5, 2019, 08:42:39 AM

Revive Therapeutics And The Psychedelic Revolution

A massive psychedelics boom is already here. In fact, with the potential to treat a wide...

Sunday, June 21, 2020, 10:30:00 AM

Revive Therapeutics Closes $23.0 Million Bought Deal Financing

Revive Therapeutics (CSE: RVV) this morning announced the closing of its bought deal financing. Originally...

Friday, February 12, 2021, 11:38:53 AM

Compass Pathways Closes Enrollment For Phase IIb Psilocybin Clinical Trial

Compass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the...

Monday, June 28, 2021, 07:37:00 AM